updated 1/7/2011 3:16:58 PM ET 2011-01-07T20:16:58

CAMBRIDGE, Mass., Jan. 7, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders, unveiled today its new corporate identity with a new corporate website.

The website, www.aegerion.com , is part of a new branding and educational effort following the Company's initial public offering in October 2010. An updated version of the Company's corporate presentation can be found in the Investor Relations section of the website in presentations at http://ir.aegerion.com/events.cfm .

In addition, Aegerion opened its new corporate headquarters in Cambridge, MA located at 101 Main Street, Cambridge, Massachusetts. The Company will also maintain an office in Bedminster, NJ. 

CEO Marc D. Beer commented, "Our new website is symbolic of the changes Aegerion faces as it moves into the commercialization phase of the Company's development. It illustrates our clinical progress and provides education to key stakeholders on our late-stage clinical product, lomitapide, a potentially life-saving therapy for homozygous familial hypercholesterolemia, a debilitating lipid disorder."

"We are delighted to start this phase of the Company in to our new headquarters in Cambridge, Massachusetts, a major hub of the biopharmaceutical industry. This will be a great home for us as we prepare for upcoming key hires and work towards marketing approvals in the U.S. and EU."

About Aegerion Pharmaceuticals, Inc.

Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The Company's lead product, lomitapide, is in Phase III clinical development. Lomitapide is initially being developed to treat patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. The Company also plans to initiate a clinical program for lomitapide to treat patients with a severe genetic form of hypertriglyceridemia called familial chylomicronemia (FC). 

This press release contains certain forward-looking statements that involve significant risks and uncertainties about Aegerion Pharmaceuticals, Inc., including statements regarding the ongoing development of the Company's product candidates and the expected timing of regulatory filings.  No forward-looking statement can be guaranteed and actual results and events may differ significantly from results and events discussed in such forward-looking statements. In particular, the risks and uncertainties include, among other things: uncertainties associated with the clinical development and associated regulatory filings of our product candidates, including the risk that our regulatory filings may not be accepted by the applicable regulatory authorities, the risk that our product candidates may not be approved for any indication, or if approved, the risk that the finally approved definition of the targeted patient populations for our product candidates may be narrower than we expect; and risks associated with our ability to recruit, hire and retain qualified personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Aegerion Pharmaceuticals, Inc. undertakes no obligation to update or revise the information contained in this release, whether as a result of new information, future events or circumstances or otherwise. For additional disclosure regarding these and other risks faced by Aegerion Pharmaceuticals, Inc., see the disclosure contained in our public filings with the Securities and Exchange Commission and available on its investor relations website at http://www.aegerion.com and on the SEC's website at http://www.sec.gov, including Aegerion Pharmaceuticals, Inc.'s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2010.

CONTACT: Aegerion Pharmaceuticals, Inc.
         Will Lewis, President
         +1 (908) 704-1300
         LaVoie Group, Inc.
         Investors & Media
         Amanda Murphy
         +1 (978) 745-4200 x107

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com